Holdings
22
Concentrated
Top 10 weight
78%
Concentration
Active share
-
Style
Equity
100%
Asset allocation
Portfolio
-Sectors
7High-conviction bets
-Top sector wt.
0.0%Cash
Market-cap allocation
Large cap53%
Mid cap38%
Small cap9%
Asset allocation
Equity100%
Top holdings
21.3%
Divi's Laboratories Ltd.EQUITY
9.0%8.9%
Cipla Ltd.EQUITY
8.9%Laurus Labs Ltd.EQUITY
6.4%Lupin Ltd.EQUITY
6.3%5.2%
Aurobindo Pharma Ltd.EQUITY
4.7%3.6%
Alkem Laboratories Ltd.EQUITY
3.5%Biocon Ltd.EQUITY
3.2%Mankind Pharma Ltd.EQUITY
3.1%Zydus Lifesciences Ltd.EQUITY
3.0%IPCA Laboratories Ltd.EQUITY
2.6%Gland Pharma Ltd.EQUITY
2.1%2.0%
Wockhardt Ltd.EQUITY
1.7%Ajanta Pharma Ltd.EQUITY
1.6%Abbott India Ltd.EQUITY
1.4%Piramal Pharma Ltd.EQUITY
1.1%TREPSCASH_EQUIVALENT
0.7%Net Current AssetsCASH_EQUIVALENT
-0.6%AI Smart summary
Pros
- Balanced across the metrics we track.
Cons
- Compact 22-stock portfolio - higher single-stock impact.
- High top-10 concentration (78%).
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Other funds in this category.
No peers found in this category.
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
99.9%